Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma (original) (raw)

Preclinical Development FcRL 5 as a Target of Antibody – Drug Conjugates for the Treatment of Multiple Myeloma

Andrew Polson

2012

View PDFchevron_right

FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

Maryann Go, Suzie Scales, Kristi Elkins

View PDFchevron_right

Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma

Douglas Leipold

Blood Cancer Journal, 2019

View PDFchevron_right

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma

Diana Franco

Antibodies, 2022

View PDFchevron_right

Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

Nimra Iftikhar

Antibodies, 2019

View PDFchevron_right

Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma

Alessandro Allegra

European Journal of Haematology, 2013

View PDFchevron_right

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf

Rita Rizzi

Pharmaceuticals, 2021

View PDFchevron_right

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Shmuel Yaccoby

Immunotherapy, 2016

View PDFchevron_right

Monoclonal antibodies in the treatment of multiple myeloma

Beth Faiman

British Journal of Haematology, 2011

View PDFchevron_right

A phase 1 dose-escalation study of antibody BI-505 in relapsed/refractory multiple myeloma

Peter Gimsing

Clinical Cancer Research, 2015

View PDFchevron_right

Data from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Titti Niskanen

View PDFchevron_right

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

Bart Barlogie

Clinical Cancer Research, 2008

View PDFchevron_right

Supplemental table 1 from A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Markus Hansson

View PDFchevron_right

Targeted therapies in multiple myeloma

Andreas Charidimou

Targeted oncology, 2009

View PDFchevron_right

The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma

Antonia Rotolo

British journal of haematology, 2016

View PDFchevron_right

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells

Diego Acosta-Alvear

The Journal of clinical investigation, 2016

View PDFchevron_right

Encouraging Debut of Immunotherapy In Myeloma

Nahla Hamed

Cancer therapy & oncology international journal, 2016

View PDFchevron_right

The Role of Targeted Therapy in Multiple Myeloma

Silvia Ling

Resistance to Targeted Anti-Cancer Therapeutics, 2021

View PDFchevron_right

Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models

Alessio Fiascarelli

Haematologica, 2020

View PDFchevron_right

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Ingemar Turesson

Leukemia, 2013

View PDFchevron_right

Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice

Roberto Castelli

Immunopharmacology and immunotoxicology, 2012

View PDFchevron_right

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor

Rita Rizzi

Frontiers in Oncology, 2021

View PDFchevron_right

Immunotherapy in Multiple Myeloma

Tajana Grenko

Frontiers Research Topics, 2019

View PDFchevron_right

Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24

Toshio Matsumoto

Blood, 1997

View PDFchevron_right

Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib

Niels van de Donk, Richard Groen, Anton Martens

Clinical cancer research : an official journal of the American Association for Cancer Research, 2014

View PDFchevron_right